The Compensatory Mechanisms in The Course of the Diastolic Dysfunction Development at Stress Cardio­myopathy

Aim     To study the activation sequence of compensatory mechanisms during the development of diastolic dysfunction.

Material and methods            The study was performed on rats with stress cardiomyopathy induced by high doses of isoproterenol (120 mg/kg twice a day). Heart function was studied 3-5 and 8-10 days after the injection by echocardiography and left ventricular (LV) catheterization. The content, isoform composition of the sarcomeric protein connectin (titin) and its mRNA content were also measured.

Results            The early period was characterized by the presence of systolic dysfunction evident as a decrease in the minute volume due to impaired myocardial  LV contractility, and slower LV filling and relaxation. Compensatory changes at this stage were manifested as increases in the left atrial volume and diastolic pause duration due to reduced contraction rate and arterial elasticity. The content of the more compliant N2BA connectin isoform and its mRNA was increased. These changes facilitated increases in LV filling and ejection. In the second period, diastolic dysfunction developed, when the minute volume, contraction rate and LV contractility became normal, although the left atrial pressure remained elevated, and the aortic diameter and LV wall thickness increased. The increased content of the N2BA isoform remained, and this was associated with stable slowing of LV relaxation.

Conclusion      The study showed that in the initial period, compensation is achieved by urgent mobilization of the circulatory system, while the improvement in myocardial contractility is secondary.

1. Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. International Journal of Cardiology. 2008;124(3):283–92. DOI: 10.1016/j.ijcard.2007.07.002

2. Shao Y, Redfors B, Scharin Täng M, Möllmann H, Troidl C, Szardien S et al. Novel rat model reveals important roles of β-adrenoreceptors in stress-induced cardiomyopathy. International Journal of Cardiology. 2013;168(3):1943–50. DOI: 10.1016/j.ijcard.2012.12.092

3. Rona G. Catecholamine cardiotoxicity. Journal of Molecular and Cellular Cardiology. 1985;17(4):291–306. DOI: 10.1016/S0022-2828(85)80130-9

4. Roof SR, Boslett J, Russell D, Del Rio C, Alecusan J, Zweier JL et al. Insulin‐like growth factor 1 prevents diastolic and systolic dysfunction associated with cardiomyopathy and preserves adrenergic sensitivity. Acta Physiologica. 2016;216(4):421–34. DOI: 10.1111/ apha.12607

5. Ikeda J, Kimoto N, Kitayama T, Kunori S. Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats. Journal of Pharmacological Sciences. 2016;132(1):65–70. DOI: 10.1016/j. jphs.2016.08.008

6. Ojha S, Goyal S, Kumari S, Arya DS. Pyruvate attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity. Experimental and Toxicologic Pathology. 2012;64(4):393–9. DOI: 10.1016/j.etp.2010.10.004

7. Tanwar V, Sachdeva J, Golechha M, Kumari S, Arya DS. Curcumin Protects Rat Myocardium Against Isoproterenol-Induced Ischemic Injury: Attenuation of Ventricular Dysfunction Through Increased Expression of Hsp27 Alongwith Strengthening Antioxidant Defense System: Journal of Cardiovascular Pharmacology. 2010;55(4):377–84. DOI: 10.1097/FJC.0b013e3181d3da01

8. Kapelko V.I., Lakomkin V.L., Lukoshkova E.V., Gramovich V.V., Viborov O.N., Abramov A.A. et al. Complex study of the rat heart at isoproterenol damage. Kardiologiia. 2014;54(3):46–56. DOI: 10.18565/cardio.2014.3.46-56

9. Willis BC, Salazar-Cantú A, Silva-Platas C, Fernández-Sada E, Ville-gas CA, Rios-Argaiz E et al. Impaired oxidative metabolism and calcium mishandling underlie cardiac dysfunction in a rat model of postacute isoproterenol-induced cardiomyopathy. American Journal of Physiology-Heart and Circulatory Physiology. 2015;308(5):H467–77. DOI: 10.1152/ajpheart.00734.2013

10. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comparative Medicine. 2009;59(4):339–43. PMID: 19712573

11. Heather LC, Catchpole AF, Stuckey DJ, Cole MA, Carr CA, Clarke K. Isoproterenol induces in vivo functional and metabolic abnormalities: similar to those found in the infarcted rat heart. Journal of Physiology and Pharmacology. 2009;60(3):31–9. PMID: 19826179

12. Rebrova TYu, Korepanov VA, Stepanov IV, Afanasiev SA. Modeling of Isoproterenol-Induced Chronic Heart Failure in 24-Month-Old Rats. Bulletin of Experimental Biology and Medicine. 2024;178(1):30–3. DOI: 10.1007/s10517-024-06277-8

13. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circulation Research. 1994;75(1):105–13. DOI: 10.1161/01.RES.75.1.105

14. Filipský T, Zatloukalová L, Mladěnka P, Hrdina R. Acute initial haemodynamic changes in a rat isoprenaline model of cardiotoxicity. Human & Experimental Toxicology. 2012;31(8):830–43. DOI: 10.1177/0960327112438927

15. Lorell BH, Isoyama S, Grice WN, Weinberg EO, Apstein CS. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts. Circulation Research. 1988;63(2):457–67. DOI: 10.1161/01.RES.63.2.457

16. Nandi SS, Katsurada K, Moulton MJ, Zheng H, Patel KP. Enhanced central sympathetic tone induces heart failure with preserved ejection fraction (HFpEF) in rats. Frontiers in Physiology. 2023;14:1277065. DOI: 10.3389/fphys.2023.1277065

17. Abramov A.A., Prosvirnin A.V., Lakomkin V.L., Kapelko V.I. Noninvasive and invasive study of the pumping function of the rat heart in myocardial infarction. Bulletin of Experimental Biology and Medicine. 2023;176(9):299–302. DOI: 10.47056/0365-9615-2023-176-9-299-302

18. Kapelko VI, Abramov AA, Lakomkin VL. Analysis of Relaxation Phase in the Rat Heart. Journal of Evolutionary Biochemistry and Physiology. 2023;59(5):1862–7. DOI: 10.1134/S0022093023050290

19. Vikhlyantsev IM, Podlubnaya ZA. New titin (connectin) isoforms and their functional role in striated muscles of mammals: Facts and suppositions. Biochemistry (Moscow). 2012;77(13):1515–35. DOI: 10.1134/S0006297912130093

20. Vikhlyantsev IM, Podlubnaya ZA. Nuances of electrophoresis study of titin/connectin. Biophysical Reviews. 2017;9(3):189–99. DOI: 10.1007/s12551-017-0266-6

21. Roof SR, Ueyama Y, Mazhari R, Hamlin RL, Hartman JC, Ziolo MT et al. CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction – A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Frontiers in Physiology. 2017;8:894. DOI: 10.3389/fphys.2017.00894

22. Lakomkin V.L., Abramov A.A., Prosvirnin A.V., Tereshchenko A.S., Arutunyan G.K., Samko A.N. et al. The Structure of Left Ventricular Relaxation in Case of Ventriculography. Kardiologiia. 2024;64(8):32–8. DOI: 10.18087/cardio.2024.8.n2640

23. Maruyama K, Natori R, Nonomura Y. New elastic protein from muscle. Nature. 1976;262(5563):58–60. DOI: 10.1038/262058a0

24. Helmes M, Trombitás K, Granzier H. Titin develops restoring force in rat cardiac myocytes. Circulation Research. 1996;79(3):619–26. DOI: 10.1161/01.res.79.3.619

25. Granzier HL, Labeit S. The Giant Protein Titin: A Major Player in Myocardial Mechanics, Signaling, and Disease. Circulation Research. 2004;94(3):284–95. DOI: 10.1161/01.RES.0000117769.88862.F8

26. Kapelko V.I. The role of sarcomeric protein titin in the pump function of the heart. Progress in Physiological Science. 2022;53(2):39– 53. DOI: 10.31857/S0301179822020059

27. Mikhailova G.Z., Vikhlyantsev I.M., Lakomkin V.L. The Role of Titin Phosphorylation in Changes in Myocardial Stiffness in Cardiomyopathies. Russian Journal of Physiology. 2024;110(3):375–98. DOI: 10.31857/S0869813924030042